{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.95","upperLimit":"100","value":"66.67"},{"groupId":"OG001","lowerLimit":"28.81","upperLimit":"64.52","value":"46.67"},{"groupId":"OG002","lowerLimit":"7.26","upperLimit":"40.74","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"25"}],"units":"Participants"}],"description":"A responder is defined by more than (90% tumor necrosis at week 13). A non-responder has less than 90% necrosis or progressive disease before week 13.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose-Finding Level 1 CR:\n\nAdult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2","id":"OG000","title":"Dose-Finding Level 1 CR"},{"description":"Regimen A: Chemoradiation plus pazopanib","id":"OG001","title":"Regimen A"},{"description":"Regimen B: Chemoradiation alone","id":"OG002","title":"Regimen B"}],"paramType":"NUMBER","populationDescription":"It was pre-specified to combine adult and pediatric participants for analysis as they received an equivalent dose of Pazopanib. There were no patients enrolled onto Dose-Finding Level 0 CR or Dose-Finding Level 2 CR. 19 Regimen A patients and 23 Regimen B patients were excluded.","reportingStatus":"POSTED","timeFrame":"Week 13 after induction","title":"Percentage of Chemoradiotherapy Patients With Positive Pathologic Response at Week 13","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}